Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Hospitalizations in Patients With Nonmalignant Short-Bowel Syndrome Receiving Home Parenteral Support

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Repeated Metabolic Balance Studies in Patients With Short Bowel Syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Teduglutide response, in terms of parenteral support (PS) volume reduction, is associated with specific disease characteristics among adults with short bowel syndrome-associated intestinal failure (SBS-IF). Whether these associations apply to PS weaning with teduglutide is unknown.

METHODS: Adults with SBS-IF treated with teduglutide in the phase III STEPS study and open-label extensions STEPS-2 and STEPS-3 were included in the analysis. Patients required PS ≥ 3 times weekly for ≥ 12 months at enrollment. The study population was stratified 3 times to create 3 distinct analysis populations based on bowel anatomy, etiology, and baseline PS volume. Outcomes included characteristics of patients who achieved PS independence and total and percentage of patients who had ≥ 1, ≥ 2, and ≥ 3 d/wk off PS at the end of STEPS, STEPS-2, and STEPS-3.

RESULTS: Eight of 39 patients who received teduglutide in STEPS obtained PS independence during the STEPS study series. Patients required > 6 months of teduglutide treatment before enteral autonomy was achieved, regardless of underlying disease characteristics. Patients who attained PS independence and greater numbers of days per week off PS tended to have lower baseline PS volumes and noninflammatory bowel disease (non-IBD) etiology. Patients with ≥ 50% colon-in-continuity showed a trend for achieving greater numbers of days per week off PS.

CONCLUSION: Although this analysis was limited by low patient numbers, results suggest that SBS-IF characteristics of lower baseline PS volume and non-IBD etiology were associated with PS reduction benefits with teduglutide in terms of days off per week and enteral autonomy.

Original languageEnglish
JournalJournal of Parenteral and Enteral Nutrition
Issue number4
Pages (from-to)697-702
Number of pages6
Publication statusPublished - May 2020

    Research areas

  • gastroenterology, independence, intestinal failure, parenteral nutrition, short bowel syndrome, weaning

ID: 59434504